Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.067
Buy
RSI(14)
52.897
Neutral
STOCH(KDJ)(9,3,3)
25.394
Sell
ATR(14)
0.625
Low Volatility
CCI(14)
32.141
Neutral
Williams %R
42.083
Buy
TRIX(12,20)
0.212
Sell
StochRSI(14)
0.000
Sell
Mediwound Ltd
MDWD18.620USD
-0.150-0.80%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
238.74MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Mediwound Ltd
Currency: USD Updated: 2025-12-22Key Insights
Mediwound Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 78/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mediwound Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.500
Target Price
+70.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mediwound Ltd Highlights
StrengthsRisks
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 20.22M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 20.22M.
Undervalued
The company’s latest PE is -10.07, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.72M shares, increasing 6.41% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.98K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.19.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Mediwound Ltd is 8.18, ranking 78/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 5.43M, representing a year-over-year increase of 24.66%, while its net profit experienced a year-over-year increase of 74.21%.
Score
Financials
8.51
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.71
Operational Efficiency
10.00
Growth Potential
7.42
Shareholder Returns
7.23
Mediwound Ltd's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Mediwound Ltd is 6.31, ranking 127/158 in the Pharmaceuticals industry. Its current P/E ratio is -10.07, which is -74.68% below the recent high of -2.55 and -128.09% above the recent low of -22.96.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 78/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Mediwound Ltd is 8.33, ranking 41/158 in the Pharmaceuticals industry. The average price target for Mediwound Ltd is 32.00, with a high of 39.00 and a low of 25.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
31.500
Target Price
+70.18%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Mediwound Ltd
MDWD
6
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Mediwound Ltd is 7.37, ranking 75/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 19.81 and the support level at 17.26, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
18.719
Sell
MA10
18.860
Sell
MA20
18.363
Buy
MA50
18.341
Buy
MA100
17.985
Buy
MA200
18.414
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Mediwound Ltd is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 44.57%, representing a quarter-over-quarter decrease of 28.07%. The largest institutional shareholder is PRFDX, holding a total of 599.38K shares, representing 4.67% of shares outstanding, with 226.07% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Clal Biotechnology Industries Ltd
Investor AB
Yelin Lapidot Provident Funds Management Ltd
Rosalind Advisors, Inc.
HOLD Alapkezelo Zrt
Israel Biotech Fund
BlackRock Institutional Trust Company, N.A.
Deep Insight Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Mediwound Ltd is 4.94, ranking 79/158 in the Pharmaceuticals industry. The company's beta value is 0.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.07
VaR
+5.63%
240-Day Maximum Drawdown
+26.75%
240-Day Volatility
+50.70%
Return
Best Daily Return
60 days
+6.21%
120 days
+13.26%
5 years
+35.08%
Worst Daily Return
60 days
-5.60%
120 days
-6.40%
5 years
-27.84%
Sharpe Ratio
60 days
+0.75
120 days
+0.05
5 years
+0.06
Risk Assessment
Maximum Drawdown
240 days
+26.75%
3 years
+48.57%
5 years
+82.22%
Return-to-Drawdown Ratio
240 days
+0.31
3 years
+0.29
5 years
-0.13
Skewness
240 days
+0.44
3 years
+1.84
5 years
+0.60
Volatility
Realised Volatility
240 days
+50.70%
5 years
+76.66%
Standardised True Range
240 days
+4.38%
5 years
+5.33%
Downside Risk-Adjusted Return
120 days
+9.27%
240 days
+9.27%
Maximum Daily Upside Volatility
60 days
+28.03%
Maximum Daily Downside Volatility
60 days
+27.02%
Liquidity
Average Turnover Rate
60 days
+0.61%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+18.51%
60 days
-16.64%
120 days
-9.16%
Peer Comparison
Pharmaceuticals
Mediwound Ltd
MDWD
6.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Mediwound Ltd?
The TradingKey Stock Score provides a comprehensive assessment of Mediwound Ltd based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Mediwound Ltd’s performance and outlook.
How do we generate the financial health score of Mediwound Ltd?
To generate the financial health score of Mediwound Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Mediwound Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Mediwound Ltd.
How do we generate the company valuation score of Mediwound Ltd?
To generate the company valuation score of Mediwound Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Mediwound Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Mediwound Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Mediwound Ltd.
How do we generate the earnings forecast score of Mediwound Ltd?
To calculate the earnings forecast score of Mediwound Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Mediwound Ltd’s future.
How do we generate the price momentum score of Mediwound Ltd?
When generating the price momentum score for Mediwound Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Mediwound Ltd’s prices. A higher score indicates a more stable short-term price trend for Mediwound Ltd.
How do we generate the institutional confidence score of Mediwound Ltd?
To generate the institutional confidence score of Mediwound Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Mediwound Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Mediwound Ltd.
How do we generate the risk management score of Mediwound Ltd?
To assess the risk management score of Mediwound Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Mediwound Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Mediwound Ltd.
